CN118304422A - 用于治疗眼部疾病或病症的药物组合物 - Google Patents

用于治疗眼部疾病或病症的药物组合物 Download PDF

Info

Publication number
CN118304422A
CN118304422A CN202410368231.1A CN202410368231A CN118304422A CN 118304422 A CN118304422 A CN 118304422A CN 202410368231 A CN202410368231 A CN 202410368231A CN 118304422 A CN118304422 A CN 118304422A
Authority
CN
China
Prior art keywords
therapeutic agent
biodegradable
pharmaceutical composition
lactide
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410368231.1A
Other languages
English (en)
Chinese (zh)
Inventor
桑吉布·库马尔·达斯
林郑文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerie Pharmaceuticals Inc filed Critical Aerie Pharmaceuticals Inc
Publication of CN118304422A publication Critical patent/CN118304422A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
CN202410368231.1A 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物 Pending CN118304422A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
US62/814,198 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders
CN202080033265.5A CN113784727B (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080033265.5A Division CN113784727B (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物

Publications (1)

Publication Number Publication Date
CN118304422A true CN118304422A (zh) 2024-07-09

Family

ID=72337143

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410368231.1A Pending CN118304422A (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物
CN202410368463.7A Pending CN118286445A (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物
CN202080033265.5A Active CN113784727B (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202410368463.7A Pending CN118286445A (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物
CN202080033265.5A Active CN113784727B (zh) 2019-03-05 2020-03-05 用于治疗眼部疾病或病症的药物组合物

Country Status (10)

Country Link
US (1) US12478577B2 (enExample)
EP (1) EP3934646A4 (enExample)
JP (3) JP7570342B2 (enExample)
KR (1) KR20210135560A (enExample)
CN (3) CN118304422A (enExample)
AU (1) AU2020232314C1 (enExample)
BR (1) BR112021017436A2 (enExample)
CA (1) CA3132635A1 (enExample)
MX (2) MX2021010599A (enExample)
WO (1) WO2020181060A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118304422A (zh) 2019-03-05 2024-07-09 爱瑞制药公司 用于治疗眼部疾病或病症的药物组合物
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
IL307997A (en) 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
TW202448436A (zh) 2023-04-11 2024-12-16 美商視爾普斯眼科公司 含有酪胺酸激酶抑制劑之眼部植入物
WO2025146683A1 (en) 2024-01-03 2025-07-10 Lyotropic Delivery Systems Ltd. Topical formulations for delivery of an active compound to the back of the eye
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
CN102014879A (zh) * 2008-04-25 2011-04-13 帝斯曼知识产权资产管理有限公司 含有具有硫酯键的聚合物的颗粒
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
KR101699497B1 (ko) * 2010-06-22 2017-01-24 도요보 가부시키가이샤 액정표시장치, 편광판 및 편광자 보호 필름
WO2012092510A2 (en) * 2010-12-29 2012-07-05 I Therapeutics, Llc Ocular drug delivery system
WO2012150265A1 (en) * 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Fiber comprising a biodegradable polymer
EP2704748B1 (en) * 2011-05-02 2018-08-15 DSM IP Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
JP6330815B2 (ja) * 2012-10-02 2018-05-30 ディーエスエム アイピー アセッツ ビー．ブイ． タンパク質および生分解性ポリエステルアミドを含む薬物送達組成物
WO2014064196A1 (en) 2012-10-24 2014-05-01 Dsm Ip Assets B.V. Fibers comprising polyesteramide copolymers for drug delivery
US20140234389A1 (en) * 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
CN105188666A (zh) 2013-04-01 2015-12-23 阿勒根公司 用于持续的眼内释放的微球药物递送系统
EP3065703A1 (en) 2013-11-08 2016-09-14 Tyrx, Inc. Polymeric drug delivery system for treating surgical complications
KR20160100992A (ko) * 2013-12-06 2016-08-24 엔비시아 테라퓨틱스 인코포레이티드 눈의 병태의 치료를 위한 전방내 이식물
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
JP7026507B2 (ja) * 2014-09-06 2022-02-28 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物
WO2016097297A1 (en) 2014-12-18 2016-06-23 Dsm Ip Assets B.V. Drug delivery system for delivery of acid sensitive drugs
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CN118304422A (zh) 2019-03-05 2024-07-09 爱瑞制药公司 用于治疗眼部疾病或病症的药物组合物

Also Published As

Publication number Publication date
AU2020232314B2 (en) 2023-10-12
JP7570342B2 (ja) 2024-10-21
EP3934646A4 (en) 2022-12-14
KR20210135560A (ko) 2021-11-15
US12478577B2 (en) 2025-11-25
BR112021017436A2 (pt) 2021-11-16
CN113784727B (zh) 2024-03-29
JP2022523548A (ja) 2022-04-25
MX2025002265A (es) 2025-04-02
JP2025004161A (ja) 2025-01-14
CN118286445A (zh) 2024-07-05
CN113784727A (zh) 2021-12-10
JP2025004160A (ja) 2025-01-14
AU2020232314A1 (en) 2021-09-30
CA3132635A1 (en) 2020-09-10
WO2020181060A1 (en) 2020-09-10
US20200306182A1 (en) 2020-10-01
AU2020232314C1 (en) 2024-03-28
MX2021010599A (es) 2021-12-10
EP3934646A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
CN113784727B (zh) 用于治疗眼部疾病或病症的药物组合物
JP5608138B2 (ja) 生分解性チロシンキナーゼインヒビター硝子体内インプラント
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
CN101984745B (zh) 用于持续释放治疗药物的药物核心
TWI501766B (zh) 製造生物可分解之玻璃體內酪胺酸激酶之植入物的方法
JP5552102B2 (ja) 長時間放出特性を有する生分解性眼インプラント
US20110009571A1 (en) Systems and methods for delivery of materials
EP2502619A2 (en) Systems and methods for delivery of materials
US20090263346A1 (en) Systems and methods for delivery of drugs
CN106132397A (zh) 用于治疗眼部疾病的前房内植入物
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
Guidetti et al. Delivery systems for the treatment of proliferative vitreoretinopathy: materials, devices and colloidal carriers
CN120897764A (zh) 包含阿西替尼多晶型物iv的眼部植入物
EP4566638A2 (en) Implant for treatment of an ocular condition
JP2023500035A (ja) 高いガラス転移温度を有するポリエステルアミドコポリマー
AU2016269432A1 (en) Biodegradable introcular tyrosine kinase inhibitor implants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240806

Address after: Fribourg

Applicant after: ALCON, Inc.

Country or region after: Switzerland

Address before: new jersey

Applicant before: Aerie Pharmaceuticals, Inc.

Country or region before: U.S.A.